Yi Larson joined Turning Point Therapeutics in August 2019 as executive vice president and chief financial officer, following a distinguished career in biotechnology investment banking at Goldman Sachs & Co. where she most recently served as a managing director of Healthcare Investment Banking.
She is responsible for corporate strategy and business development, finance, information technology, human resources, and will serve as principal financial officer.
In her role at Goldman Sachs, Ms. Larson worked with a variety of biotechnology boards and management teams on a range of strategic financial matters, including capital and financing strategy; executing public stock offerings and other financings; as well as leading buy- and sell-side transactions. She has successfully executed more than 50 deals, including $30 billion in financing and $70 billion in mergers and acquisitions.
She graduated from The Wharton School at the University of Pennsylvania with an MBA concentrated in Finance. She also earned a master’s degree in Electrical Engineering and Computer Science and a bachelor’s degree in Electrical Engineering, both from MIT.